Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-Secretion Caused by Treatment With Antiepileptic Medicine
Patients treated with the antiepileptic drug Oxcarbazepine often develop syndrome of inappropriate secretion of antidiuretic hormone(SIADH)We want to test the hypothesis, that these patients have a higher reabsorption of water during the Aquaporine2 water channels,a higher concentration of Vasopressine (AVP), and a lower clearance of water.This situation will tend to normalize, when the patients...
Brief Summary
Official Title: “Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-Secretion Caused by Treatment With Antiepileptic Medicine”
Patients treated with the antiepileptic drug Oxcarbazepine often develop syndrome of inappropriate secretion of antidiuretic hormone(SIADH)We want to test the hypothesis, that these patients have a higher reabsorption of water during the Aquaporine2 water channels,a higher concentration of Vasopressine (AVP), and a lower clearance of water.This situation will tend to normalize, when the patients are treated with fluid restriction
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Detailed Clinical Trial Description
The purpose of the study is to determine the amount of Aquaporine2(AQP2)in the urine in patients treated with the antiepileptic drug Oxcarbazepine before and after the administration of fluid restriction
Intervention(s) in this Clinical Trial
- Procedure: fluid restriction for 14 days (15ml fluid per kg weight)
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Age more than 18 years, both men and women, patients with epilepsia treated with Oxcarbazepine, and a Sodium content in plasma lower than 130 mmol/liter
Exclusion Criteria:
- severe diseases in the heart, lungs or liver;diabetes mellitus, other not-well treated diseases in endocrine organs, cancer; unwillingness to participate
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: Holstebro Hospital Other
Overall Clinical Trial Officials and Contacts
Erling B Pedersen, Professor Study Chair Holstebro Hospital, Denmark
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00298753
Study ID Number: MED.RES.HOS.2005.04/IMT
ClinicalTrials.gov Identifier: NCT00298753
Health Authority: Denmark: Ethics Committee
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00298753
